MICROORGANISMS FOR PREVENTING AND TREATING NEOPLASMS ACCOMPANYING CELLULAR THERAPY

• US 20110064650A1
• Filed: 05/15/2009
• Published: 03/17/2011
• Est. Priority Date: 05/16/2008
• Status: Abandoned Application

• Current Assignee: Aladar A. Szalay
• Original Assignee: Aladar A. Szalay
• Inventors: Szalay, Aladar A.
• Application Number:
  US12/736,826
• Publication Number:
  US 20110064650A1
• Time in Patent Office: Days
• US Class Current: 424/1.11
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/17 Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes when activated by a specific antigen A61K39/00
• CPC Class Codes: A61K 35/545 Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
• CPC Class Codes: A61K 35/768 Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
• CPC Class Codes: A61K 38/19 Cytokines; Lymphokines; Interferons
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12N 2710/24132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Abstract

Provided are methods for using cellular compositions in combination with oncolytic viruses. The methods include administering oncolytic viruses for the inhibition and treatment of tumors caused by administration of cellular therapies, such as stem cell therapies. The methods also include contacting cellular compositions with oncolytic viruses for the removal of neoplastic cells prior to administration of the cellular composition for therapy. Diagnostic methods for monitoring treatment also are provided.

Claims

1. A method for inhibiting the development of a tumor resulting from cellular therapy in a subject receiving a cellular therapy, comprising:

(a) administering a cellular therapy composition to a subject; and

(b) systemically administering an oncolytic virus to the subject, wherein the oncolytic virus is administered in an amount sufficient to treat or prevent formation of tumors from contaminating tumor cells in the cellular therapy composition.

2. The method of claim 1, where the cellular therapy composition comprises stem cells, bone marrow cells, immune cells, non-immune cells or cells comprising a gene therapy vector.

7. The method of claim 1, wherein the virus and the cellular therapy composition are administered simultaneously, sequentially or intermittently.

8. The method of claim 1, wherein the cellular therapy composition is pre-treated with the virus prior to administration.

9. The method of claim 1, wherein the cellular therapy composition is administered systemically.

12. The method of claim 1, wherein the virus is administered in a single administration or multiple administrations.

13. The method of claim 1, wherein the virus is administered after the cellular therapy composition.

14. The method of claim 1, wherein the virus is administered intravenously, or mucosally.

24. The method of claim 1, wherein the cellular therapy composition treats a disease or disorder selected from among cardiovascular disease, cancer, diabetes, spinal cord injury, neurodegenerative disease, Alzheimer'"'"'s disease, Parkinson'"'"'s disease, multiple sclerosis, Amyotrophic lateral sclerosis, Duchenne Muscular Dystrophy, muscle damage or dystrophy, stroke, burns, lung disease, retinal disease, kidney disease, osteoarthritis, and rheumatoid arthritis.

25. The method of claim 1, wherein the cellular therapy composition comprises a cancer stem cells, and the virus infects the cancer stem cells in the cellular therapy composition.

36. The method of claim 1, wherein the virus is a vaccinia virus.

37. The method of claim 1, wherein the virus is a Lister strain virus.

38. The method of claim 37, wherein the virus is LIVP.

39. The method of claim 37, wherein the virus is selected from among, GLV-1h68, GLV-1i69, GLV-1h70, GLV-1h71, GLV-1h72, GLV-1h73, GLV-1h74, GLV-1h81, GLV-1h82, GLV-1h83, GLV-1h84, GLV-1h85, GLV-1h86, GLV-1j87, GLV-1j88, GLV-1j89, GLV-1h90, GLV-1h91, GLV-1 h92, GLV-1h96, GLV-1h97, GLV-1h98, GLV-1h100, GLV-1h101, GLV-1h139, GLV-1h104, GLV-1h105, GLV-1h106, GLV-1h107, GLV-1h108, GLV-1h109, GLV-1h146, GLV-1h150, GLV-1h151, GLV-1h152 and GLV-1h153.

40. The method of claim 1, wherein the virus is a pox virus.

42. The method of claim 1, further comprising detecting the virus in the subject.

43. The method of claim 42, wherein the virus is detected by fluorescence imaging, magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), positron emission tomography (PET), scintigraphy, gamma camera, β

+ detector, a γ

detector or a combination thereof.

44. The method of claim 1, wherein the virus encodes a detectable protein or a protein that induces a detectable signal.

45. The method of claim 44, wherein the detectable protein is selected from among a luciferase or a fluorescent protein.

46. The method of claim 1, wherein the virus encodes a therapeutic gene product.

47. The method of claim 46, wherein the therapeutic gene product is an anti-cancer agent or anti-angiogenic agent.

48. The method of claim 47, wherein the therapeutic gene product is selected from among a cytokine, a chemokine, an immunomodulatory molecule, an antigen, an antibody or fragment thereof, antisense RNA, prodrug converting enzyme, siRNA, angiogenesis inhibitor, a toxin, an antitumor oligopeptide, a mitosis inhibitor protein, an antimitotic oligopeptide, an anti-cancer polypeptide antibiotic, a transporter protein, and tissue factor.

49. The method of claim 1, further comprising administering an anticancer agent.

50. The method of claim 49, wherein the anticancer agent is selected from among a cytokine, a chemokine, a growth factor, a photosensitizing agent, a toxin, an anti-cancer antibiotic, a chemotherapeutic compound, a radionuclide, an angiogenesis inhibitor, a signaling modulator, an anti-metabolite, an anti-cancer vaccine, an anti-cancer oligopeptide, a mitosis inhibitor protein, an antimitotic oligopeptide, an anti-cancer antibody, an anti-cancer antibiotic, an immunotherapeutic agent, hyperthermia or hyperthermia therapy, a bacterium, radiation therapy and a combination of any of the preceding.

3-6. -6. (canceled)

10-11. -11. (canceled)

15-23. -23. (canceled)

26-35. -35. (canceled)

41. (canceled)

51-76. -76. (canceled)